Bluejay Therapeutics

Bluejay Therapeutics is a company developing innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay Therapeutics was founded in 2020 by Keting Chu. Bluejay Therapeutics headquarters are located in San Mateo, California.

Mirum Pharmaceuticals acquires Bluejay Therapeutics, a company developing innovative cures for infectious diseases with the first target indication of chronic HBV infection.


Mirum Pharmaceuticals intends to acquire Bluejay Therapeutics, a company developing innovative cures for infectious diseases with the first target indication of chronic HBV infection.